Search the Newsreel

First Bancorp (FBNC) Could Be 30% Below Fair Value Following Its Revenue Beat

Should Coca-Cola Consolidated’s Higher Sales but Lower Profit Require Action From Coca-Cola Consolidated (COKE) Investors?

After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why

Bank of the James president buys $2,705 in company stock

Michael A. Syrek, President of Bank of the James, recently purchased 100 shares of the company's common stock for $27.05 per share, totaling $2,705. This transaction, occurring on August 7, 2026, was reported earlier than legally required. The purchase follows a 100% return on …

BofA Securities Maintains Aardvark Therapeutics(AARD.US) With Sell Rating

BofA Securities has reiterated its Sell rating on Aardvark Therapeutics (AARD.US). The article does not provide further details regarding the financial implications or the analyst's rationale for maintaining this rating.

Corcept therapeutics chief development officer sells $1.8m in stock

William Guyer, Chief Development Officer at Corcept Therapeutics Inc. (NASDAQ:CORT), sold shares worth approximately $1.85 million on August 10, 2026, through two separate transactions under a 10b5-1 plan. Despite the sales, which occurred while the stock was near its 52-week high, Guyer also acquired …

Is Iovance Biotherapeutics (IOVA) Undervalued As Q2 Earnings Reaffirm Revenue Guidance?

Diluted earnings per share (diluted EPS) of Spero Therapeutics, Inc. – BMV:SPRO

Bill Gates’ Portfolio Just Added Home Depot (HD) Despite Risks. Time to Buy?

Latest filings show the Bill & Melinda Gates Foundation Trust opened a new position in Home Depot (NYSE:HD), worth about $353 million, during the second quarter. The stock is down about 15% over the past year. What's plaguing HD? High mortgage rates and inflation …

Relmada (RLMD) Q2 2026 Earnings Call Transcript

BMO Capital Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $20

BMO Capital has initiated coverage on MapLight Therapeutics (MPLT.US) with a Buy rating and set a price target of $20. This indicates a positive outlook from the investment firm regarding the company's future stock performance.

Avalo Therapeutics CMO Mittie Doyle sells $13,580 in stock

Mittie Doyle, CMO at Avalo Therapeutics (NASDAQ:AVTX), sold 679 shares for $13,580 after exercising stock options under a Rule 10b5-1 trading plan. Following these transactions, she directly holds 51,776 shares and 114,413 stock options. This news follows Avalo's inclusion in the Russell 2000 and …

Notable trades: Netflix, Coca-Cola, Pfizer among notable names

Insider transactions were seen across major firms this week, including Netflix (NFLX [https://seekingalpha.com/symbol/NFLX]), Merck (MRK [https://seekingalpha.com/symbol/MRK]), and Pfizer (PFE [https://seekingalpha.com/symbol/PFE]). The following trades took place between August 10 and August 14. * Netflix (NFLX [https://seekingalpha.com/symbol/NFLX]) Chief Financial Officer Spencer Neumann sold 9,248 shares at …

MOS Stock Hits Over 5-Year Lows – Why Did Mosaic Withdraw Its Phosphate Production Guidance For 2026?

NTLA|Intellia Therapeutics Inc|Price:11.910|Chg%:+0.080

PTC Therapeutics Is Maintained at Overweight by Barclays

Barclays has reiterated its 'Overweight' rating on PTC Therapeutics (PTCT). The analyst firm maintained a price target of $70.00 for the company's stock. This indicates a positive outlook from Barclays regarding PTC Therapeutics' future performance.

Home Depot and Lowe's Have Both Raised Their Dividends for 17 Straight Years. Which Stock Is the Smarter Buy Heading Into Earnings?

Home Depot (NYSE: HD) and Lowe's (NYSE: LOW) have long dominated the home improvement space in the U.S. In past decades, they drove massive growth and dividend returns for their investors as they expanded nationwide. Although Home Depot operates in Canada and Mexico, both …

Nasdaq, S&P 500 Futures Edge Lower Ahead Of Fed Week, AI Earnings Test: Why POET, ATOM, OGN, QCOM, NTLA Are In Focus

HLS Therapeutics Inc. (TSE:HLS) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Ruby Mills Ltd. is Rated Sell

Outlook Therapeutics (OTLK) CFO Lawrence Kenyon buys 101K shares plus 101K warrants

Outlook Therapeutics' CFO, Lawrence A. Kenyon, purchased 101,010 shares of common stock and 101,010 accompanying warrants in an underwritten public offering on August 14, 2026. The combined offering price was $0.99 per share and warrant, with the warrants immediately exercisable at $1.10 and expiring …

Die Walt-Disney-Aktie steigt nach starken Quartalszahlen und Avengers-Fantasie

Protagonist Therapeutics (NASDAQ:PTGX) Screens as an Affordable Growth Opportunity

Theravance Biopharma Deal Faces Investor Probe

Halper Sadeh LLC is investigating the proposed acquisition of Theravance Biopharma (NASDAQ: TBPH) by Zymeworks Inc. for $17 per share in cash plus a contingent value right. The investigation aims to determine if Theravance shareholders are receiving a fair price and if the company's …

TJX Companies (TJX) Could Be 14% Undervalued As Growth Narrative Holds

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Fresh earnings expectations put TJX Companies (TJX) in focus, with Wall Street projecting quarterly earnings of $1.18 per share and US$15.14b in revenue, offering …

XORTX Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock

Edgewise Therapeutics CEO Kevin Koch sold $785,042 worth of company stock on August 12, 2026, primarily to cover tax obligations related to Restricted Stock Unit vesting. Despite the sales, Mr. Koch also acquired new shares through vesting and was granted additional RSUs and stock …

Walleye Capital LLC Takes $1.59 Million Position in PTC Therapeutics, Inc. $PTCT

Walleye Capital LLC has acquired a new position in PTC Therapeutics, Inc., purchasing 19,522 shares valued at approximately $1.59 million during the second quarter. Several other institutional investors also increased their holdings in the biopharmaceutical company, which has an average analyst rating of "Moderate …

LENZ Therapeutics (NASDAQ:LENZ) Stock Rating Upgraded by Zacks Research

Walleye Capital LLC Purchases New Shares in Kyverna Therapeutics, Inc. $KYTX

Oppenheimer Asset Management Inc. Makes New $21.08 Million Investment in HealthEquity, Inc. $HQY

Oppenheimer Asset Management Inc. has initiated a significant new investment in HealthEquity, Inc. (NASDAQ:HQY), acquiring 233,378 shares valued at approximately $21.08 million. This investment comes as HealthEquity reported strong quarterly earnings, beating analyst estimates with $1.24 per share and a 7.2% revenue increase. The …

Walleye Capital LLC Purchases New Stake in Aquestive Therapeutics, Inc. $AQST

Walleye Capital LLC has acquired a new stake of 282,568 shares in Aquestive Therapeutics, Inc. (NASDAQ:AQST), valued at approximately $1.18 million. Institutional investors collectively hold 32.45% of the company's stock, while insider ownership stands at 6.81%. Despite a wider-than-expected quarterly loss, analysts maintain a …

TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share. The investigation focuses on whether Theravance's board failed to secure the best possible price, conducted a fair sales process, …

Plan Group Financial LLC Invests $3.59 Million in Southern Company (The) $SO

Plan Group Financial LLC recently invested $3.59 million in Southern Company, acquiring 37,485 shares. Other institutional investors also adjusted their holdings, with a total of 64.1% of the stock owned by hedge funds and institutions. Southern Company reported better-than-expected EPS but slightly missed revenue …

Mineralys Therapeutics (NASDAQ:MLYS) Downgraded by Zacks Research to "Strong Sell"

Zacks Research downgraded Mineralys Therapeutics (NASDAQ:MLYS) to a "Strong Sell" rating, despite a mixed analyst sentiment with an average "Hold" rating and a $49.33 price target. The downgrade follows a significant earnings miss, with the company reporting a quarterly loss of $2.85 per share …

Zacks Research Downgrades Monopar Therapeutics (NASDAQ:MNPR) to Hold

Zacks Research downgraded Monopar Therapeutics (NASDAQ:MNPR) from a "strong-buy" to a "hold" rating, despite the broader analyst consensus remaining a "moderate buy" with an average price target of $117.42. The company's shares opened at $113.04, trading near their 12-month high, and it recently reported …